Market Place
Sourcing Support
Viralgen Invests In AAV Vector Characterization Service
19 Jul 2024 //
PRESS RELEASE
Investments for the creation of a new Quality Control laboratory
19 Jul 2024 //
PRESS RELEASE
Viralgen Opens New MSAT Lab For Advanced Therapies Research
14 May 2024 //
PRESS RELEASE
Viralgen Commercial Therapeutic Advances Gene Therapy Efforts
12 Feb 2024 //
PRESS RELEASE
Viralgen Vector Core Leads Joint Gene Therapy Development
08 Feb 2024 //
PRESS RELEASE
Viralgen Welcomes Back Andy Holt as CCO
19 Oct 2023 //
ACCESSWIRE
Viralgen & Elpida Partner for SPG50 & CMT4J Trials
28 Sep 2023 //
ACCESSWIRE
Viralgen and Elpida Therapeutics partner to manufacture gene therapy medicines
28 Sep 2023 //
GLOBENEWSWIRE
Viralgen GMP certification rAAV commercial product
09 Jan 2023 //
GLOBENEWSWIRE
Viralgen Expands Capacity with cGMP Certification
09 Jan 2023 //
CONTRACTPHARMA
Viralgen is infusing $142M into its viral vector operations
01 Jul 2021 //
FIERCEPHARMA
Viralgen is infusing $142M into its viral vector operations
30 Jun 2021 //
FIERCEPHARMA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.